Bonk, Inc. (NASDAQ:BNKK – Get Free Report) saw a large decrease in short interest in October. As of October 30th, there was short interest totaling 116,256 shares, a decrease of 46.6% from the October 15th total of 217,655 shares. Approximately 2.7% of the shares of the stock are sold short. Based on an average daily volume of 98,113 shares, the days-to-cover ratio is currently 1.2 days.
Bonk Price Performance
Shares of NASDAQ:BNKK opened at $0.91 on Monday. Bonk has a 1 year low of $0.85 and a 1 year high of $8.90. The stock has a market capitalization of $7.25 million, a price-to-earnings ratio of -0.24 and a beta of 1.86. The company’s 50 day simple moving average is $1.31 and its 200 day simple moving average is $1.97.
Bonk (NASDAQ:BNKK – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.76) earnings per share for the quarter. Bonk had a negative return on equity of 137.47% and a negative net margin of 952.21%. The business had revenue of $1.16 million for the quarter.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bonk in a research note on Thursday, October 22nd. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Bonk currently has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on Bonk
Hedge Funds Weigh In On Bonk
An institutional investor recently bought a new position in Bonk stock. BlackRock Inc. acquired a new position in shares of Bonk, Inc. (NASDAQ:BNKK – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,188 shares of the company’s stock, valued at approximately $50,000. BlackRock Inc. owned about 0.41% of Bonk as of its most recent SEC filing. Institutional investors own 12.55% of the company’s stock.
About Bonk
Safety Shot, Inc., a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners.
Further Reading
- Five stocks we like better than Bonk
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Bonk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bonk and related companies with MarketBeat.com's FREE daily email newsletter.
